Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03999996 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 365
- Enrollment target
NCT03999996 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 365 participants.
The verdict
NCT03999996, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 365 participants
- Enrollment target
Study Summary
The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315 (NCT03341637) (Mexico) and for up to 36 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-304 (NCT03423173) (United States \[US\]) and to describe the impact of a tetravalent dengue vaccine (TDV) booster dose vs placebo on antibody response for each of the 4 dengue serotypes at 1 month and 6 months post administration of the TDV booster or placebo.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2019-11-12 |
| Est. Completion | 2024-05-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03999996
The ClinicalTrials.gov registry entry for NCT03999996 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03999996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03999996 about?
NCT03999996 is a clinical study titled "Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose". The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315 (NCT03341637) (Mexico) and for up to 36 months after the first vaccination in ...
What is the current status of trial NCT03999996?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 365 participants. The study started on 2019-11-12. Estimated completion is 2024-05-25.
What interventions are being tested in trial NCT03999996?
The interventions under investigation include: Placebo (BIOLOGICAL), Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03999996?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.